Phar­ma firms make new pledge to launch in all Eu­ro mar­kets at least 2 years post-au­tho­riza­tion

As part of a dri­ve to in­crease new meds across Eu­rope, mem­ber com­pa­nies of the con­ti­nent’s largest phar­ma lob­by­ing or­ga­ni­za­tion have set a new goal to seek pric­ing and re­im­burse­ment in all EU coun­tries no lat­er than 2 years af­ter cen­tral EU mar­ket­ing au­tho­riza­tion.

Ac­cord­ing to EF­PIA, the pledge should sub­stan­tial­ly in­crease the avail­abil­i­ty of in­no­v­a­tive med­i­cines in EU coun­tries and de­crease the time pa­tients must wait for new med­i­cines by sev­er­al months. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER